Head to Head Survey: CannTrust (OTCMKTS:CNTTF) vs. Zymeworks (NASDAQ:ZYME)

CannTrust (OTCMKTS:CNTTF) and Zymeworks (NASDAQ:ZYME) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Risk & Volatility

CannTrust has a beta of 4.52, suggesting that its stock price is 352% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

Profitability

This table compares CannTrust and Zymeworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CannTrust	N/A	N/A	N/A
Zymeworks	-126.92%	-37.97%	-25.31%

Valuation and Earnings

This table compares CannTrust and Zymeworks”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CannTrust	$15.96 million	0.00	$7.39 million	$0.07	N/A
Zymeworks	$105.96 million	16.38	-$81.13 million	($1.37)	-17.35

CannTrust has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than CannTrust, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.1% of CannTrust shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for CannTrust and Zymeworks, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CannTrust	0	0	0	0	0.00
Zymeworks	1	1	8	1	2.82

Zymeworks has a consensus price target of $36.67, indicating a potential upside of 54.26%. Given Zymeworks’ stronger consensus rating and higher probable upside, analysts plainly believe Zymeworks is more favorable than CannTrust.

About CannTrust

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

About Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.